An experienced developer of therapeutics across multiple areas of drug discovery, from target discovery through IND.

Dr. Long brings to ROME extensive experience in the development of therapeutics across a broad range of therapeutic areas, including musculoskeletal and neuromuscular disorders, metabolic dysfunction, and inflammatory disorders. Dr. Long most recently was the Head of Biology at Casma Therapeutics, where she and her team worked to develop and characterize novel autophagy-based degraders for use in multiple therapeutic areas. Before Casma Therapeutics, she held multiple positions at Scholar Rock, where she was closely involved with development of the anti-proMyostatin antibody apitegromab, and where she led the efforts of the exploratory biology team. Dr. Long also held positions at Ironwood Pharmaceuticals and Pfizer.

Dr. Long received a B.A. in molecular and cellular biology from Northwestern University and a Ph.D. in Biological Sciences from Stanford University.